H
IV gene therapy offers a potential alternative treatment strategy for HIV-infected individuals compared to the use of current antiretroviral drugs, which, after prolonged use, can become toxic and allow for the generation of escape mutants (7, 11, 20, 24, 26, 29) . A recent hematopoietic stem cell (HSC) transplant for acute myeloid leukemia in an HIV-infected patient was performed utilizing allogeneic cells from an individual homozygous for the ⌬32 CCR5 deletion (12, 14, 19) . HIV-1 suppression has been observed in the recipient to date, even after halting antiretroviral drug therapy (16) . The report of the success of this stem cell transplant is the first to describe a functional cure of an HIVinfected individual and brings about a realization that stem cell therapies for HIV-infected patients can have a dramatic impact on the outcome of their disease (15) . Therefore, HIV stem cell gene therapy offers the possibility to mimic the results of this transplant by engineering a patient's autologous HSCs to express anti-HIV genes, thus conferring resistance to infection (27) . Advantages in utilizing HSCs for HIV gene therapy include the reconstitution of an HIV-resistant immune system, the potential for lifelong protection from further HIV replication, and the possibility of a onetime treatment upon transplantation of anti-HIV gene-modified HSCs (27) .
Numerous anti-HIV genes have been designed to inhibit HIV replication; however, the use of a single anti-HIV gene may not be sufficient to protect cells long-term from infection due to the high mutation rate of HIV (1, 3, 4, 13, 18, (21) (22) (23) . This has been proven through the use of monotherapy with small-molecule antiretroviral drugs, which eventually select for viral escape mutants (7, 20, 26) . Therefore, similar to combination approaches with smallmolecule drugs, multiple anti-HIV genes inserted into a single gene therapy vector could potentially confer stronger protection from HIV infection in the long term while also preventing the generation of viral resistance (2, 5, 9, 10) .
Anti-HIV genes targeted to block the early stages of HIV infection, including attachment and entry, reverse transcription, and integration, offer a number of advantages over molecules which act at later stages of infection, including preventing the generation of provirus and the continued replenishment of viral reservoirs, which are major reasons for the failure to cure HIV-infected individuals (1, 3, 4, 25, 28) . In this regard, by combining multiple preintegration anti-HIV genes into a single vector, potent preintegration protection from HIV infection could be conferred (5, 17) . In a previous report by our group, strong preintegration protection from HIV-1 infection, in vitro, was established by a triple-combination anti-HIV lentiviral vector containing a human/rhesus macaque TRIM5␣ isoform, a CCR5 short hairpin RNA (shRNA), and a TAR decoy (5) . This vector not only prevented HIV integration in challenged cells but also blocked the generation of escape mutants.
For the preclinical analysis of anti-HIV genes and vectors, it is necessary to utilize an appropriate in vivo model capable of demonstrating safety and efficacy of the novel therapy (6, 8) . The
NOD-RAG1
Ϫ/Ϫ IL2r␥ Ϫ/Ϫ double mutant (NRG) mouse model offers the potential to evaluate multilineage human hematopoiesis from intrahepatic injection of human CD34 ϩ HSCs into newborn mice. Three months after transplantation, functional human T cells, B cells, and macrophages can be detected in lymphoid organs, including the spleen, thymus, and bone marrow (6) . Mice successfully engrafted with a human immune system can be infected with HIV and display normal HIV disease characteristics, including CD4
ϩ cell depletion and an increase in plasma viremia (6) . This mouse model offers a unique preclinical in vivo system to evaluate anti-HIV gene therapy molecules in human cells at a level acceptable to regulatory agencies.
In our current studies, the preclinical safety and efficacy of a combination anti-HIV lentiviral vector was evaluated, in vivo, in a humanized NRG mouse model. Here we demonstrate multilineage human hematopoiesis from anti-HIV lentiviral vector-transduced CD34
ϩ HSCs in the peripheral blood and in various lymphoid organs, including the thymus, spleen, and bone marrow. After in vivo challenge with either an R5-tropic BaL-1 or an X4-tropic NL4-3 strain of HIV-1, maintenance of human CD4 ϩ cells and a selective survival advantage were observed in mice containing the anti-HIV vector-transduced cells. The data provided here confirm the utility of this combination anti-HIV lentiviral vector in inhibiting HIV infection in a stem cell gene therapy setting and validate its potential for application in a future human clinical trial.
MATERIALS AND METHODS
Lentiviral vector design and production. The construction of the combination anti-HIV lentiviral vector has been described previously (5) . Briefly, a third-generation self-inactivating lentiviral vector, CCLc-MNDU3-x-PGK-EGFP (control vector), which contains an enhanced green fluorescent protein (EGFP) reporter gene and was used as the EGFP-alone control vector, was utilized to construct the combination anti-HIV vector (5) . The chimeric human/rhesus macaque TRIM5␣ gene under the control of the MNDU3 promoter, a CCR5 shRNA under the control of a human polymerase III U6 promoter, and a TAR decoy under the control of a human polymerase III U6 promoter were inserted upstream of the phosphoglycerate kinase (PGK)-driven EGFP reporter gene to derive CCLc-combination-anti-HIV (Fig. 1a) (3-5, 22, 25) .
Lentiviral vectors were generated in HEK-293T packaging cells. Twenty-five micrograms of the packaging construct, p⌬8.9 (containing gag and pol genes), 25 g of CCLc-MNDU3-x-PGK-EGFP (EGFP-alone control empty vector [EGFP-alone]) or CCLc-combination-anti-HIV (transfer vector), and 5 g of vesicular stomatitis virus G (VSVG) (envelope) were vector, CCLc-x-PGK-EGFP, was utilized to generate the combination anti-HIV construct. (a) A human/rhesus macaque TRIM5␣ isoform was driven under the control of the MNDU3 promoter, and a CCR5 shRNA and a TAR decoy were driven under separate human polymerase III U6 small RNA promoters. These three anti-HIV genes were inserted upstream from the EGFP reporter gene. (b) CD34
ϩ HSCs were transduced with the control EGFP-alone vector or the anti-HIV vector and transplanted into NRG pups. Transplanted mice were screened for human CD45 and EGFP expression in the peripheral blood for engraftment of transduced cells, either EGFP-alone (n ϭ 12) or anti-HIV (n ϭ 14). (c) The peripheral blood of nontransduced (NT) (n ϭ 14), EGFP-alone (n ϭ 12), and anti-HIV (n ϭ 14) cell-engrafted mice was analyzed for human T cells with antibodies specific for CD3 and CD4 and also for expression of EGFP. (d) CD4 ϩ human splenocytes were analyzed for the expression of CCR5 (n ϭ 5 for EGFP-alone and n ϭ 11 for anti-HIV). Bar graphs display averages and standard deviations for each cohort. Statistical significance (P Ͻ 0.05) is represented by an asterisk.
transfected into HEK-293T packaging cells in T225 flasks by lipofection. Vector supernatants were collected at 48 h posttransfection and concentrated 100-fold by ultrafiltration. Titers of vectors were subsequently determined on HEK-293T cells, and the titers obtained ranged from 2 ϫ 10 9 to 6 ϫ 10 9 transducing units/ml.
Transduction of primary human CD34
؉ HSCs. CD34 ϩ hematopoietic stem cells (HSCs) were isolated from umbilical cord blood (NDRI, Philadelphia, PA) with Ficoll-Paque (GE Healthcare, Piscataway, NJ) and purified by magnetic bead column separation (Miltenyi Biotec, Auburn, CA). CD34
ϩ cell isolation purity of Ͼ93% was routinely obtained. Total CD34 ϩ cells were cultured in complete Iscove modified Dulbecco medium (IMDM) containing 10% fetal bovine serum (FBS) and supplemented with 50 ng/ml stem cell factor (SCF), Flt-3 ligand, and thrombopoietin (TPO). Cells were transduced with the EGFP-alone lentiviral vector or the anti-HIV combination vector (multiplicity of infection [MOI] of 10) for 3 h at 37°C with 8 g/ml protamine sulfate.
Transplantation and screening of NRG mice. NOD-RAG1
Ϫ/Ϫ IL2r␥ Ϫ/Ϫ double mutant (NRG) mice (stock number 007799) were obtained from The Jackson Laboratory (Sacramento, CA) and were used in compliance with institutional and IACUC guidelines and regulations. Two-to 5-day-old newborn NRG pups were sublethally irradiated with 200 cGy of gamma irradiation. Nontransduced, EGFP-alone-transduced (control), or anti-HIV vector-transduced HSCs (3 ϫ 10 5 total cells/ mouse) were injected intrahepatically into irradiated pups. At 3 months posttransplantation, mice were bled retro-orbitally and the peripheral blood was analyzed by fluorescence-activated cell sorting (FACS) for EGFP and human leukocytes with a phycoerythrin (PE)-Cy7-conjugated anti-human CD45 antibody (clone HI30), an allophycocyanin (APC)-conjugated CD3 antibody (clone HIT3A), and a PE-conjugated CD4 antibody (clone RPA-T4) (BD Biosciences, San Jose, CA).
FACS analysis of engrafted human immune cells. To evaluate multilineage hematopoiesis in transplanted NRG mice, cells from the peripheral blood and various lymphoid organs, including the thymus, spleen, and bone marrow, were stained with anti-human antibodies and analyzed by FACS. T cells were stained with an APC-conjugated CD3 antibody (clone HIT3A), a PE-conjugated CD4 antibody (clone RPA-T4), or an APC-conjugated CD8 antibody (clone RPA-T8) (BD Biosciences, San Jose, CA). B cells were stained with a PE-conjugated CD19 antibody (clone HIB19) (BD Biosciences, San Jose, CA). Macrophages were stained with a PE-conjugated CD14 antibody (clone M5E2) (BD Biosciences, San Jose, CA). To detect cell surface expression of CCR5, cells were stained with a PE-conjugated anti-human antibody (clone 2D7) (BD Biosciences, San Jose, CA). Cells were also evaluated for EGFP expression to determine the levels of engraftment of vector-transduced cells. Isotype controls used were a PE-conjugated mouse IgG1 (clone MOPC-21) (BD Biosciences, San Jose, CA), a PE-conjugated mouse IgG2a (clone IC003P) (RND Systems, Minneapolis, MN), and an APC-conjugated mouse IgG1 (clone MOPC-21) (BD Biosciences, San Jose, CA). FACS analysis was performed on a Beckman Coulter FC-500 instrument.
In vivo HIV-1 challenge of engrafted NRG mice. To determine whether the anti-HIV gene-modified cells were resistant to HIV-1 infection, engrafted mice were challenged in vivo with either an R5-tropic BaL-1 or an X4-tropic NL4-3 strain of HIV-1. BaL-1 virus was obtained from the NIH AIDS Research Reference and Reagent Program and grown in CD34 ϩ cell-derived macrophages. To grow the stock virus, macrophages were infected with an MOI of 1.0 and cell culture supernatants were collected on various days postinfection. Viral titers were obtained using the Ghost cell assay. Briefly, Ghost-R5-X4-R3 cells were infected with serial dilutions of stock virus. At 48 hours postinfection, the Ghost cells were analyzed by flow cytometry for EGFP expression to obtain an infectious viral titer. For NL43, an infectious clone was obtained from the NIH AIDS Research Reference and Reagent Program and transfected into 293T cells. At 72 hours posttransfection, cell culture supernatants were collected, and titers were determined on Ghost-R5-X4-R3 cells by the Ghost cell assay.
Mice were infected intravenously (i.v.) with 200,000 total infectious units. On various weeks postinfection, peripheral blood draws were taken and analyzed for total human CD4 ϩ cell percentage by FACS and for HIV plasma viremia by quantitative PCR (Q-PCR). For FACS analysis, the cells were stained with a PE-Cy7-conjugated CD45 antibody (clone HI30), an APC-conjugated CD3 antibody (clone HIT3A), and a PE-conjugated CD4 antibody (clone RPA-T4) (BD Biosciences, San Jose, CA). The EGFP percentage was also analyzed to determine the levels of vector-transduced cells. FACS analysis was performed on a Beckman Coulter FC-500 instrument.
To determine the levels of plasma viremia, viral RNA was extracted from plasma specimens from infected mice using a Qiagen viral RNA extraction kit (Qiagen, Valencia, CA). Reverse transcription with oligo(dT) primers was then performed using TaqMan RT reagents (Applied Biosystems, Carlsbad, CA). Quantitative PCR was then performed using SYBR green (Applied Biosystems, Carlsbad, CA) and a primer/probe set specific for the HIV pol gene: primers 5=-CTGGCTACTATTTCTTTTGC TA-3= and 5=-TGGCATGGGTACCAGCACA-3= and probe 5=-TTTATC TACTTGTTCATTTCCTCCAATTCCTT-3= (IDT DNA Technologies, Coralville, IA). Q-PCR was performed on an Applied Biosystems 7200 analyzer.
In 5 cells/well) were stimulated with 1 g/ml interleukin-2 (IL-2) and 1 g/ml phytohemagglutinin (PHA). On day 3 poststimulation, the cells were challenged at an MOI of 0.05 with either an R5-tropic BaL-1 or an X4-tropic NL43 strain of HIV-1. On various days postinfection, culture supernatants were collected and analyzed by p24 antigen enzyme-linked immunosorbent assay (ELISA).
Cytokine secretion from in vivo-derived T cells. Splenocytes from engrafted mice were isolated and sorted based on EGFP expression. These sorted cells were further purified for human CD3 ϩ T cells by magnetic bead separation (Miltenyi Biotec, Auburn, CA). CD3 ϩ T cells, either control nontransduced or EGFP ϩ anti-HIV gene-modified cells (1 ϫ 10 6 cells/well) were stimulated with 1 g/ml IL-2 and 1 g/ml phytohemagglutinin. On day 3 poststimulation, culture supernatants were collected and analyzed by FACS for expression of IL-4, IL-6, IL-10, tumor necrosis factor alpha (TNF-␣), and gamma interferon (IFN-␥) using a BD cytokine bead array kit (BD Biosciences, San Jose, CA).
Karyotyping. To determine if the anti-HIV vector-transduced mobilized peripheral blood CD34
ϩ HSCs maintained their chromosomal and genetic stability, karyotyping was performed. Upon transduction, EGFP-positive cells were sorted based on EGFP expression and further cultured for 5 days in Methocult semisolid methylcellulose medium enriched with cytokines (Stem Cell Technologies, Vancouver, Canada) to promote robust proliferation. The cells were washed twice with complete Dulbecco modified Eagle medium (DMEM) with 10% FBS to dissolve the methylcellulose and then treated with colcemid, a mitotic inhibitor, for 30 min at 37°C to arrest the cells in metaphase. Cells were subsequently treated with cell stripper for 10 min at 37°C, followed by treatment with a KCl hypotonic solution and 3:1 methanolacetic acid fixative solutions. Karyotyping slides were made and Giemsa banded. Karyotyping was performed on an Olympus Bx41 microscope with a DP20 camera. Analysis was performed with an Applied imaging system. Statistical analysis. t tests were used to compare the differences between different treatments of the study interest. The statistical analyses were conducted in R (version 2.10.1) for Windows. A significance level of 0.05 was used in hypothesis testing.
RESULTS

Successful engraftment of anti-HIV vector-transduced CD34
؉ HSCs. A third-generation self-inactivating combination anti-HIV lentiviral vector expressing a human/rhesus macaque chimeric TRIM5␣, a CCR5 shRNA, a TAR decoy, and an EGFP reporter gene was utilized in our experiments (Fig. 1a) . Expression of all three anti-HIV genes has been previously demonstrated in vectortransduced cells (5) . The control empty vector, EGFP-alone, does not contain any anti-HIV genes but does contain the PGK-EGFP reporter gene (5) . To evaluate the potential of combination anti-HIV vector-transduced CD34 ϩ HSCs to engraft NRG mice, FACS analysis was performed on transplanted mice. As displayed in Fig.  1b , successful engraftment of transduced cells was observed in the peripheral blood. The average engraftment of EGFP-alone vectortransduced cells was 21.9%, with a standard deviation of 9.4%, and the average engraftment of anti-HIV vector-transduced cells was 17.5%, with a standard deviation of 8.0%. The percentages obtained were from total human leukocytes stained with an antihuman CD45 antibody. No significant difference (P ϭ 0.213) between engraftment of EGFP-alone and anti-HIV vector-transduced cells was observed.
To determine the levels of CD4 ϩ T cell development in anti-HIV vector-transduced cell-engrafted mice, peripheral blood was stained with anti-human CD3 and CD4 antibodies (Fig. 1c) . No significant difference (P ϭ 0.063 and P ϭ 0.420, respectively) in ϩ T cells with a standard deviation of 9.0%). Representative flow cytometry plots are displayed below the bar graphs in Fig. 1 . Table 1 displays peripheral blood engraftment results from nontransduced and EGFP-alone-and anti-HIV vector-transduced cell-transplanted mice. These results demonstrate that no cytotoxic effects were observed with the anti-HIV vector-transduced cells in the peripheral blood of engrafted mice.
To determine the levels of CCR5 downregulation of anti-HIV vector-transduced cells (cells which express the CCR5 shRNA), flow cytometry was performed on total human (CD4 ϩ /EGFP ϩ ) splenocytes from mice engrafted with EGFP-alone or anti-HIV vector-transduced cells. As displayed in Fig. 1d , anti-HIV vectortransduced cells expressed significantly (P ϭ 0.002) decreased levels of cell surface CCR5 (7.4% positive) compared to control EGFP-alone vector-transduced cells (46.4% positive).
Multilineage human hematopoiesis from anti-HIV vectortransduced cells in lymphoid organs. To determine if normal engraftment and multilineage hematopoiesis of anti-HIV vectortransduced cells had occurred in the lymphoid organs of transplanted NRG mice, flow cytometry was performed (Fig. 2) . Single cells were isolated from the thymus, spleen, and bone marrow of engrafted mice and stained with respective antibodies as described in Materials and Methods. Table 2 displays lymphoid organ engraftment results from nontransduced and EGFP-alone-and anti-HIV vector-transduced cell-transplanted mice. No significant difference (P Ͼ 0.05) was observed with engraftment or development of anti-HIV gene-modified T cells (CD3 ϩ ) in the peripheral blood, thymus, or spleen compared to that in nontransduced or EGFP-alone cell-engrafted mice. No observed differences in the size of the thymus grafts were noted between the engrafted mice. No significant difference (P Ͼ 0.05) was observed with engraftment or development of anti-HIV gene-modified B cells in the spleen or bone marrow compared to that in nontransduced or EGFP-alone cell-engrafted mice. The only significant difference observed in lymphoid organ engraftment of anti-HIV gene-modified cells (average, 11.88%; standard deviation, 1.78%) compared to nontransduced cells (average, 29.17%; standard deviation, 3.95%) was with CD14 ϩ /CD45 ϩ cells in the bone marrow (P ϭ 0.005). However, no significant difference (P ϭ 0.112) in engraftment of bone marrow CD14 ϩ /CD45 ϩ cells was observed when comparing the levels of EGFP-alone (average, 6.3%; standard deviation, 2.43%) and anti-HIV vector-transduced cells. These results demonstrated that no cytotoxic effects were observed with the anti-HIV vector-transduced HSCs, as they were capable of engrafting and undergoing multilineage hematopoiesis in various lymphoid organs of transplanted NRG mice at levels equivalent to those for control HSCs. Representative flow cytometry plots are displayed in Fig. 2 .
Maintenance of CD4 ؉ T cell levels in anti-HIV cell-engrafted mice upon in vivo HIV-1 infection. To determine whether resistance to HIV-1 infection was conferred in anti-HIV vector-transduced cell-engrafted mice, the levels of total human CD4 ϩ cells in the peripheral blood were analyzed by flow cytometry at various weeks postinfection. Maintenance of normal human CD4 ϩ levels was observed in anti-HIV cell-engrafted mice (solid lines) upon challenge with either an R5-tropic BaL-1 (Fig. 3a) or an X4-tropic NL43 (Fig. 3b ) strain of HIV-1. In the anti-HIV gene-modified cell-engrafted mice (solid lines), total human CD4 ϩ T cell percentages gated on human CD45 ϩ leukocytes ranged between 46.2 and 65.4% and between 37.5 and 79.2% at the end of the challenge experiment with BaL-1 or NL43 HIV-1, respectively. This was in comparison to control EGFP-alone vector-transduced cell-engrafted mice (dashed lines), where total human CD4 ϩ T cell percentages gated on human CD45 ϩ cells declined over the course of infection and ranged from 19.1 to 29.1% and from 5.9 to 15.1% at the end of the challenge experiment with BaL-1 or NL43 HIV-1, respectively. The average levels of CD4 ϩ T cells preinfection and at the end of the challenge experiments are displayed in Fig. 3c and d for BaL-1 and NL4-3 infections, respectively. In EGFP-alone cellengrafted mice infected with BaL-1, CD4
ϩ T cell levels decreased to an average of 25.8%, which was significantly different (P ϭ 0.002) from those in anti-HIV cell-engrafted mice, where average CD4 ϩ T cell levels were 55.1% (Fig. 3c) . A significant difference (P ϭ 0.001) was also observed in the average level of CD4 ϩ T cells in EGFP-alone cell-engrafted mice (9.1%) infected with NL4-3 compared to the average level of anti-HIV CD4 ϩ T cells (58.4%) (Fig. 3d) . Representative flow cytometry plots demonstrating CD4 ϩ cell levels in the infected mice are displayed below the bar graphs in Fig. 3 . These results demonstrated that the combination anti-HIV vector significantly enhanced survival of human T cells in the face of an HIV infection.
To evaluate the levels of human CD4 ϩ cells in the lymphoid organs of infected mice, mice were sacrificed at the end of the challenge experiments and human CD4 ϩ T cells from the spleen ϩ HSCs that were either nontransduced (NT) or transduced with a control EGFP-alone vector or the anti-HIV lentiviral vector. Upon engraftment, various lymphoid organs, including the spleen (a), thymus (b), and bone marrow (c), were analyzed for human cell engraftment. Flow cytometry was performed to detect EGFP expression along with total human leukocytes (CD45), T cells (CD3, CD4, and CD8), B cells (CD19), and macrophages (CD14). Data are representative of mice for each cohort. Complete data sets for each cohort of mice are included in Table 2. were analyzed. As displayed in Fig. 4a , upon infection with BaL-1, human CD4 ϩ T cell levels were maintained in the spleen (average of 53.8% of human CD3 ϩ T cells, with a standard deviation of 8.6%) in anti-HIV vector-transduced cell-engrafted mice. This was in comparison to mice engrafted with control EGFP-alone vector-transduced cells, which displayed a significantly (P ϭ 0.002) decreased level of CD4 ϩ human T cells in the spleen (average of 23.3%, with a standard deviation of 7.5%). As displayed in Fig. 4b , upon infection with NL4-3, human CD4 ϩ T cell levels were maintained in the spleen (average of 67.4% of human CD3 ϩ T cells, with a standard deviation of 9.3%) in anti-HIV vectortransduced cell-engrafted mice. This was in comparison to mice engrafted with control EGFP-alone vector-transduced cells, which displayed a significantly (P ϭ 0.001) decreased level of CD4 ϩ human CD3 ϩ T cells in the spleen (average of 3.2%, with a standard deviation of 1.4%). Representative flow cytometry plots demonstrating CD4 ϩ cell levels in the infected mice are displayed below the bar graphs in Fig. 4 . These results demonstrate that normal CD4
ϩ cell levels could be maintained during the course of an HIV infection in a cell population which contained CD4 ϩ cells derived from anti-HIV gene-modified HSCs. Fig. 5a ) or an NL43 (Fig. 5b ) strain of HIV-1 from preinfection to the time of euthanizing the mice. During infection with BaL-1 (Fig. 5a) , the levels of anti-HIV gene-modified CD4 ϩ cells increased, on average, 0.95-fold, with a standard deviation of 0.35-fold. This was a significant increase (P ϭ 0.006) compared to those in control EGFP-alone vector-transduced cells, which decreased 0.03-fold, with a standard deviation of 0.17-fold. In mice infected with NL4-3 (Fig. 5b) , the levels of anti-HIV gene-modified CD4 ϩ cells increased 1.60-fold, with a standard deviation of 0.54-fold. This was a significant increase (P ϭ 0.005) compared to those in control EGFP-alone vector-transduced cells, which increased 0.05-fold, with a standard deviation of 0.30-fold. These results demonstrate that in the presence of an HIV-1 infection, in vivo, cells expressing anti-HIV genes have a selective survival advantage and an increase in their percentage of total cells due to their ability to resist infection and the killing of unprotected cells.
Detection of plasma viremia and resistance of anti-HIV gene-modified cells upon ex vivo HIV-1 challenge. A hallmark of successfully engrafted NRG mice is their ability to display plasma viremia upon infection with HIV-1 (6) . Therefore, to determine if the levels of plasma viremia had decreased in HIV-1-infected NRG mice engrafted with anti-HIV vector-transduced HSCs, Q-PCR was performed on plasma specimens from mice at various weeks postinfection. As demonstrated in Fig. 6 , the mice engrafted with anti-HIV vector-transduced cells did not display a decrease in HIV-1 plasma viremia over the course of infection. Levels of HIV-1 RNA copies per milliliter remained between 7 and 8 log units in the anti-HIV cell-engrafted mice, which were similar to those in control cell-engrafted mice (Fig. 6 ). These results were observed for both the R5-tropic BaL-1 (Fig. 6a ) and X4-tropic NL43 (Fig. 6b ) challenge experiments.
To evaluate whether HIV-1 resistance could be conferred when a pure population of anti-HIV vector-transduced cells was challenged with HIV-1, EGFP ϩ and EGFP Ϫ human CD3 ϩ T cells were sorted from the spleens of successfully engrafted mice. Upon stimulation with IL-2 and PHA for 3 days postsorting, the cells were challenged with either R5-tropic BaL-1 (Fig. 6c) or X4-tropic NL43 (Fig. 6d) at an MOI of 0.05. At various days postinfection, cell culture supernatants were collected and analyzed for HIV-1 p24 by antigen ELISA. As displayed in Fig. 6 , a strong reduction in HIV output (Ͼ4 log units) was observed in the sorted anti-HIV vector-transduced cell culture compared to the nontransduced cell culture. These results demonstrate that pure populations of anti-HIV gene-transduced cells isolated from engrafted animals, when faced with an HIV-1 viral load, display potent resistance to infection, coupled with strongly diminished HIV-1 production.
Anti-HIV gene-modified cells are functional and retain a normal karyotype. To determine whether the anti-HIV genemodified cells were functionally normal, the levels of secretion of specific cytokines were measured. T cells from the spleens of engrafted mice were purified and sorted based on EGFP and human CD3 expression. The T cells were stimulated with IL-2 and PHA and cultured for 3 days. At day 3 poststimulation, culture super- natants were collected and analyzed by FACS for expression of IL-4, IL-6, IL-10, TNF-␣, and IFN-␥ using a BD cytokine bead array. As displayed in Fig. 7a , no significant difference (P Ͼ 0.05) in the secretion of any of the cytokines measured was detected in the anti-HIV gene-modified cell cultures compared to control nontransduced cells. These data show that transduction had not affected normal cytokine secretion from the T cells.
With the transduction of CD34 ϩ HSCs with a combination anti-HIV lentiviral vector and their subsequent differentiation toward hematopoietic lineages, it is possible that chromosomal and genetic abnormalities could arise. Therefore, karyotyping analyses were performed on anti-HIV vector-transduced CD34 ϩ HSCs. As displayed in Fig. 7b , the anti-HIV cells retained a normal chromosome profile. Normal banding was observed, and no translocations or other detectable chromosomal abnormalities were detected.
The results obtained from these experiments demonstrated that the anti-HIV T cells appear to be functionally normal and that the transduction and expression of the anti-HIV genes did not cause any gene rearrangements or abnormalities in chromosome organization.
DISCUSSION
Stem cell gene therapy for HIV has the potential to offer an alternative therapeutic approach for HIV-infected individuals (27) . With the possibility of a one-time treatment by transducing selfrenewing and self-repopulating HSCs with potent anti-HIV genes, the removal of small-molecule antiretroviral drug therapy and the control of HIV replication could occur, with the development of a complete HIV-resistant immune system. This has been demonstrated with a bone marrow transplant in Berlin, Germany, where an HIV-infected individual received allogeneic HSCs from a donor who was homozygous for the CCR5-⌬32-bp allele (14) . The recipient is currently free from HIV replication while also having discontinued antiretroviral drug therapy (16) . The results from this study highlight the potential use of HIV-resistant stem cells to provide a functional cure for HIV-infected patients (15) .
In our current study, we evaluated the in vivo safety and effi- cacy of triple-combination anti-HIV lentiviral vector-transduced CD34
ϩ HSCs in a NOD-RAG1 Ϫ/Ϫ IL2r␥ Ϫ/Ϫ double mutant (NRG) mouse model. This anti-HIV vector contains three highly potent anti-HIV genes which individually confer strong resistance to HIV-1 infection. However, due to the high mutation rate of HIV, its ability to generate escape variants, and the various tropisms of the virus, it is critical to develop combination therapies which act at multiple stages of the HIV life cycle. This has been demonstrated with the use of monotherapy small-molecule antiretroviral drugs, which eventually give rise to viral escape mutants (7, 20, 26) . Therefore, similar to combination approaches with antiretroviral drugs, multiple anti-HIV genes inserted into a single gene therapy vector may offer stronger protection from HIV infection and will have a greater chance of preventing viral resistance.
The use of multiple HIV resistance genes, however, is not the only aspect to consider when designing HIV gene therapies. The specific stage of the life cycle targeted and the mechanism of action of the anti-HIV gene also need to be taken into consideration. Anti-HIV genes which block early stages of HIV infection, including attachment and entry (CCR5 shRNA) and reverse transcription and integration (TRIM5␣), will prevent the generation of provirus and viral reservoirs, which are main reasons for the failure to cure HIV-infected individuals (1, 3-5, 25, 28) . In our previous study evaluating the in vitro efficacy of this combination vector (CCR5 shRNA, human/rhesus TRIM5␣, and a TAR decoy), strong preintegration protection from HIV-1 infection was observed (5) . This anti-HIV vector not only prevented viral integration but also blocked the generation of viral escape variants, 
